# Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

> **NCT00612222** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 4 (actual)

## Conditions studied

- Metastatic Melanoma
- Skin Cancer

## Interventions

- **BIOLOGICAL:** autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
- **BIOLOGICAL:** ALVAC MART-1 Vaccine
- **BIOLOGICAL:** aldesleukin
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00612222
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The study was terminated due to low accrual.
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612222, "Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00612222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*